The trial is designed to assess both safety and preliminary efficacy. Read more…
The US FDA has lifted the clinical hold and cleared ACT’s Investigational New Drug (IND) application to (immediately) initiate a Phase I/II multicenter study Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.